Designed, developed, and delivered by CEC Oncology

Neurofibromatosis type 1 (NF1) is a complex condition of immense clinical gravity, and though the traditional management paradigm has long been circumscribed by a limited and ineffectual trimodal combination of surgery, radiation, and surveillance, the recent emergence of trial data in support of targeted medical therapies is renewing horizons for NF1 patients and their families. MEK inhibitors, in particular, are making a tangible impact in this treatment space and are the first pharmacologic class to demonstrate meaningful clinical responses in NF1-associated tumors, with one agent, selumetinib, achieving FDA approval to-date and others poised to follow.

Given this seismic shift in the NF1 treatment landscape, oncology nurses are optimally positioned to serve a sentinel role on the interprofessional, multidisciplinary NF1 care team. Not only are nurses the first point of contact for many NF1 patients, caregivers, and families when initiating treatment, but they also are the preeminent healthcare provider for longitudinal follow-up assessment, toxicity monitoring, patient/family education, and the provision of critical social and emotional support infrastructures.

CEC Oncology collaborated with top experts, Dr. Jaishri Blakeley, Shannon Langmead, and Connie DiDomenico to bring “Navigating Novel Terrain in Neurofibromatosis Type 1: An Interactive Road Map for the Oncology Nurse in the Era of Targeted Therapy” to the ONS Annual Congress on Tuesday, April 27th, and the full session is now available On-Demand!

Access the On-Demand session at your convenience anytime between now and Monday, May 31st at the following link:

Thank you!